Apoptosis in selected liver diseases

Turkish Journal of Gastroenterology

Volumn 20, Issue 3, 2009, Pages 171-179

  Kiliçarslan, Alp ^a,b   Kahraman, Alişan ^a   Akkiz, Hikmet ^b   Yildiz Menziletoǧlu, Şule ^c   Fingas, Christain D ^a   Gerken, Guido ^a   Canbay, Ali ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HACETTEPE UNIVERSITY   (Turkey)

^c CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Alcoholic liver disease; Apoptosis; HBV; HCV; Hepatocellular carcinoma; Non alcoholic steatohepatitis

Indexed keywords

ALCOHOL; ALPHA SMOOTH MUSCLE ACTIN; CHEMOKINE; COLLAGEN TYPE 1; COLLAGENASE; CYTOCHROME C; CYTOCHROME P450 2E1; CYTOKERATIN 18; DEATH RECEPTOR; DEATH RECEPTOR 5; FAS ANTIGEN; FAS LIGAND; FIBRONECTIN; GLIOTOXIN; HEPATITIS B VIRUS X PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; METALLOPROTEINASE; PERFORIN; PLACEBO; PREDNISOLONE; PROTEIN BCL 2; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALCOHOL LIVER DISEASE; APOPTOSIS; BLEEDING; CALCIUM MOBILIZATION; CELL DEATH; CELL PERMEABILIZATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; DRUG FATALITY; DRUG MECHANISM; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FIBROGENESIS; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION; KIDNEY FAILURE; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PROTEIN EXPRESSION; REVIEW; VIRUS HEPATITIS;

APOPTOSIS; HUMANS; LIVER; LIVER DISEASES;

EID: 70350145459     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2009.0003     Document Type: Review

References (100)

1. Kerr J. History of the events leading to the formulation of the apoptosis concept. Toxicology 2002; 181-182: 471-474 (Pubitemid 36015740)
2. Kerr J, Wyllie A, Currie A. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257
3. Patel T, Roberts L, Jones B, Gores G. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis 1998; 18: 105-114 (Pubitemid 28224002)
4. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008; 134: 1641-1654 (Pubitemid 351615416)
5. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006; 43: 31-44.
6. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39: 273-278 (Pubitemid 38222163)
7. Galle PR, Krammer PH. CD95-induced apoptosis in human liver disease. Semin Liver Dis 1998; 18: 141-151 (Pubitemid 28224005)
8. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485
9. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23: 217-226 (Pubitemid 37052447)
10. Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-176
11. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54: 1024-1033 (Pubitemid 40873921)
12. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312
13. Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001; 2: 627-633
14. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784-788 (Pubitemid 30780741)
15. Thornberry NA. Caspases: key mediators of apoptosis. Chem Biol 1998; 5: R97-103.
16. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000; 108: 567-574
17. Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? Hepatology 2001; 34: 3-6.
18. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776
19. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-1330
20. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351 (Pubitemid 36362792)
21. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250
22. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-436
23. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metal-loproteinase inhibitors. J Clin Invest 1998; 102: 538-549 (Pubitemid 28376157)
24. Issa R, Williams E, Trim N, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548-557 (Pubitemid 32234801)
25. Saile B, Knittel T, Matthes N, et al. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol 1997; 151: 1265-1272 (Pubitemid 27479756)
26. Taimr P, Higuchi H, Kocova E, et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37: 87-95. (Pubitemid 36042149)
27. Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121: 685-698 (Pubitemid 32822584)
28. Issa R, Zhou X, Trim N, et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 2003; 17: 47-49
29. Bechmann LP, Zahn D, Gieseler RK, et al. Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells. Hepatol Res 2009; 39: 601-608
30. Lawson JA, Fisher MA, Simmons CA, et al. Parenchymal cell apoptosis as a signal for sinusoidal sequestration and transendothelial migration of neutrophils in murine models of endotoxin and Fas-antibody-induced liver injury. Hepatology 1998; 28: 761-767
31. Jaeschke H. Inflammation in response to hepatocellular apoptosis. Hepatology 2002; 35: 964-966
32. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-1198 (Pubitemid 37314827)
33. Maher JJ, Scott MK, Saito JM, Burton MC. Adenovirusmediated expression of cytokine-induced neutrophil chemoattractant in rat liver induces a neutrophilic hepatitis. Hepatology 1997; 25: 624-630
34. Maher JJ, Gores GJ. Apoptosis: silent killer or neutron bomb? Hepatology 1998; 28: 865-867
35. Jaeschke H. Neutrophil-mediated tissue injury in alcoholic hepatitis. Alcohol 2002; 27: 23-27 (Pubitemid 34626480)
36. Faouzi S, Burckhardt BE, Hanson JC, et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem 2001; 276: 49077-49082 (Pubitemid 37370613)
37. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231
38. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42: 650-656 (Pubitemid 41233658)
39. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474
40. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 (Pubitemid 40770284)
41. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 (Pubitemid 41002048)
42. Kahraman A, Miller M, Gieseler RK, et al. Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: two cases. Eur J Gastroenterol Hepatol 2006; 18: 101-105 (Pubitemid 43004890)
43. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-194
44. Adams LA, Angulo P, Abraham SC, et al. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis. Liver Int 2006; 26: 298-304. (Pubitemid 43349319)
45. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443 (Pubitemid 36929425)
46. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-1717 (Pubitemid 39237497)
47. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867
48. Yoon JH, Gores GJ. Death receptor-mediated apoptosis and the liver. J Hepatol 2002; 37: 400-410
49. Feldstein AE, Canbay A, Guicciardi ME, et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003; 39: 978-983 (Pubitemid 37523769)
50. Purohit V, Brenner DA. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 2006; 43: 872-878
51. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
52. Goldin RD, Hunt NC, Clark J, Wickramasinghe SN. Apoptotic bodies in a murine model of alcoholic liver disease: reversibility of ethanol-induced changes. J Pathol 1993; 171: 73-76 (Pubitemid 23294692)
53. Ghavami S, Hashemi M, Kadkhoda K, et al. Apoptosis in liver diseases - detection and therapeutic applications. Med Sci Monit 2005; 11: RA337-45. (Pubitemid 41695499)
54. Natori S, Rust C, Stadheim LM, et al. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001; 34: 248-253 (Pubitemid 32176446)
55. Ziol M, Tepper M, Lohez M, et al. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J Hepatol 2001; 34: 254-260 (Pubitemid 32176447)
56. Kurose I, Higuchi H, Miura S, et al. Oxidative stress-mediated apoptosis of hepatocytes exposed to acute ethanol intoxication. Hepatology 1997; 25: 368-378 (Pubitemid 27069057)
57. Kurose I, Higuchi H, Kato S, et al. Oxidative stress on mitochondria and cell membrane of cultured rat hepatocytes and perfused liver exposed to ethanol. Gastroenterology 1997; 112: 1331-1343 (Pubitemid 27157547)
58. Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 1999; 19: 2098-2108 (Pubitemid 29098268)
59. McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993; 13: 170-182
60. Costelli P, Aoki P, Zingaro B, et al. Mice lacking TNFalpha receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell Death Differ 2003; 10: 997-1004. (Pubitemid 37069477)
61. Poynard T, Thabut D, Chryssostalis A, et al. Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol 2003; 38: 518-520
62. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448-455
63. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530 (Pubitemid 24264998)
64. Luster AD. Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445
65. Mita E, Hayashi N, Iio S, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204: 468-474 (Pubitemid 24343944)
66. Luo KX, Zhu YF, Zhang LX, et al. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases. J Viral Hepat 1997; 4: 303-307
67. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic Tcell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-652 (Pubitemid 24270685)
68. Lee JY, Chae DW, Kim SM, et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J Viral Hepat 2004; 11: 130-135 (Pubitemid 38365763)
69. Piccoli C, Scrima R, D'Aprile A, et al. Mitochondrial dysfunction in hepatitis C virus infection. Biochim Biophys Acta 2006; 1757: 1429-1437 (Pubitemid 44442124)
70. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci U S A 1997; 94: 8744-8749 (Pubitemid 27335110)
71. Pan J, Duan LX, Sun BS, Feitelson MA. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappa B. J Gen Virol 2001; 82: 171-182 (Pubitemid 32045807)
72. Feitelson MA, Reis HM, Lale Tufan N, et al. Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease. Cancer Lett 2009 Feb 5 [Epub ahead of print].
73. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078-1087 (Pubitemid 39425563)
74. Bantel H, Lugering A, Poremba C, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001; 34: 758-767 (Pubitemid 32928001)
75. Feldstein AE, Gores GJ. An apoptosis biomarker goes to the HCV clinic. Hepatology 2004; 40: 1044-1046
76. Volkmann X, Cornberg M, Wedemeyer H, et al. Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 2006; 43: 1311-1316 (Pubitemid 43980110)
77. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997; 229: 68-76. (Pubitemid 27243489)
78. Machida K, Tsukiyama-Kohara K, Seike E, et al. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem 2001; 276: 12140-12146 (Pubitemid 37385380)
79. Machida K, Cheng KT, Lai CK, et al. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 2006; 80: 7199-7207 (Pubitemid 44025216)
80. Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 622-634 (Pubitemid 350055563)
81. Gomaa AI, Khan SA, Toledano MB, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308
82. Kaczynski J, Hansson G, Wallerstedt S. Clinical features in hepatocellular carcinoma and the impact of autopsy on diagnosis. A study of 530 cases from a low-endemicity area. Hepatogastroenterology 2005; 52: 1798-1802
83. Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006; 5: 16-24.
84. Rocken C, Carl-McGrath S. Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 2001; 19: 269-278
85. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
86. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787-3800 (Pubitemid 43980474)
87. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004; 64: 5078-5083 (Pubitemid 39006522)
88. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004; 24: 77-88. (Pubitemid 38496050)
89. Zhao J, Zhang X, Shi M, et al. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. Hepatology 2006; 44: 205-215 (Pubitemid 44049153)
90. Chen RF, Li ZH, Zou SQ, Chen JS. Effect of hepatitis C virus core protein on modulation of cellular proliferation and apoptosis in hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 71-74 (Pubitemid 40347518)
91. Okimoto T, Yahata H, Itou H, et al. Safety and growth suppressive effect of intra-hepatic arterial injection of AdCMV-p53 combined with CDDP to rat liver metastatic tumors. J Exp Clin Cancer Res 2003; 22: 399-406. (Pubitemid 37205396)
92. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366 (Pubitemid 26391458)
93. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 1996; 2: 1361-1366
94. Jing X, Ueki N, Cheng J, et al. Induction of apoptosis in hepatocellular carcinoma cell lines by emodin. Jpn J Cancer Res 2002; 93: 874-882 (Pubitemid 35012248)
95. Huang DS, Shen KZ, Wei JF, et al. Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2. World J Gastroenterol 2005; 11: 204-207
96. Zheng JY, Yang GS, Wang WZ, et al. Overexpression of Bax induces apoptosis and enhances drug sensitivity of hepatocellular cancer-9204 cells. World J Gastroenterol 2005; 11: 3498-3503
97. Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact 2009; 179: 131-144
98. Sha H, Ma Q, Jha RK, et al. Resveratrol ameliorates hepatic injury via the mitochondrial pathway in rats with severe acute pancreatitis. Eur J Pharmacol 2008; 601: 136-142
99. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004; 23: 6702-6711 (Pubitemid 39280002)
100. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15: 513-520